Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Kudchadkar on Immunotherapy in Merkel Cell Carcinoma

January 10th 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Dr. Landi Discusses the Importance of Screening in Melanoma

January 9th 2018

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the importance of screening in melanoma.

Adjuvant Pembrolizumab Improves RFS in Melanoma

January 9th 2018

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Dr. Carvajal Discusses the Biology of Extracutaneous Melanoma

January 4th 2018

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

January 3rd 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

January 2nd 2018

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

The Future of Treatment for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017

Darolutamide's Role in Treating Nonmetastatic CRPC

December 28th 2017

MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

The Value of AR-Targeted Therapy in CRPC

December 28th 2017

Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

Treating Advanced Bladder Cancer in the Future

December 28th 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

December 28th 2017

Immunotherapy in Second-Line Advanced Bladder Cancer

December 28th 2017

Monitoring for Treatment Response in Advanced Bladder Cancer

December 28th 2017

x